ALKS Q3 2018 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$249M+14.4% YoY

Gross Profit

$209M84.2% margin

Operating Income

-$37M-14.9% margin

Net Income

-$34M-13.8% margin

EPS (Diluted)

$-0.22

QoQ Revenue Growth

-18.4%

Cash Flow

Operating Cash Flow

$33M

Free Cash Flow

$17M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$610M

Stockholders' Equity

$1.2B

Cash & Equivalents

$216M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$249M	$217M	+14.4%
Gross Profit	$209M	$181M	+15.4%
Operating Income	-$37M	-$38M	+3.1%
Net Income	-$34M	-$36M	+5.1%

Revenue Segments

Vivitrol

$80M39%

Invega Sustenna Or Xeplion And Invega Trinza

$66M32%

Aristada

$36M17%

B Y D U R E O N

$12M6%

A M P Y R A Or F A M P Y R A

$7M4%

R I S P E R D A L C O N S T A

$4M2%

Other Products And Services

$2M1%